{"id":"NCT03084471","sponsor":"AstraZeneca","briefTitle":"An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies.","officialTitle":"An Open-Label, Multi-Centre, Safety Study of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-06-05","primaryCompletion":"2020-03-31","completion":"2022-12-16","firstPosted":"2017-03-21","resultsPosted":"2021-06-15","lastUpdate":"2022-12-22"},"enrollment":867,"design":{"allocation":"NON_RANDOMIZED","model":"SEQUENTIAL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Advanced Solid Malignancies"],"interventions":[{"type":"BIOLOGICAL","name":"MEDI4736 (Durvalumab)","otherNames":[]},{"type":"BIOLOGICAL","name":"MEDI4736 (Durvalumab) + Tremelimumab","otherNames":[]}],"arms":[{"label":"Combination therapy","type":"EXPERIMENTAL"},{"label":"Monotherapy","type":"EXPERIMENTAL"}],"summary":"To evaluate the safety, tolerability, and anti-tumor activity of the combination of durvalumab + tremelimumab or durvalumab alone in different solid tumors.","primaryOutcome":{"measure":"Number of Participants With Adverse Events of Special Interest (AESIs)","timeFrame":"From screening to safety follow up visit (90 days after last dose), up to approximately 3 years.","effectByArm":[{"arm":"AESI","deltaMin":265,"sd":null},{"arm":"AEPI","deltaMin":300,"sd":null},{"arm":"imAE","deltaMin":97,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":79,"countries":["United States","Canada","France","Germany","Italy","Netherlands","South Korea","United Kingdom"]},"refs":{"pmids":["35042068"],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D4191C00068&amp;attachmentIdentifier=67484637-c120-4784-9f00-aae6e369b5f2&amp;fileName=D4191C00068_CSP_redacted.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D4191C00068&amp;attachmentIdentifier=8e9421af-9880-4525-a031-c1e541b74a5c&amp;fileName=D4191C00068_SAP_redacted.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":254,"n":867},"commonTop":["Asthenia","Anaemia","Constipation","Decreased appetite","Diarrhoea"]}}